Open-label, single center, phase I trial to investigate the mass balance and absolute bioavailability of the oral c-Met inhibitor tepotinib

被引：0
|
作者：
Johne, A. [1 ]
Scheible, H. [2 ]
Becker, A. [1 ]
Van Lier, J. J. [3 ]
Meyring, M. [2 ]
机构：
[1] Merck KGaA, Global Early Dev, Darmstadt, Germany
[2] Merck KGaA, Inst Drug Metab & Pharmacokinet, Grafing, Germany
[3] Pharmaceut Res Assoc, Early Dev Serv, Zuidlaren, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30232-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
369
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [1] Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers
    Johne, Andreas
    Scheible, Holger
    Becker, Andreas
    van Lier, Jan Jaap
    Wolna, Peter
    Meyring, Michael
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1507 - 1519
  • [2] Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers
    Andreas Johne
    Holger Scheible
    Andreas Becker
    Jan Jaap van Lier
    Peter Wolna
    Michael Meyring
    Investigational New Drugs, 2020, 38 : 1507 - 1519
  • [3] Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).
    Falchook, Gerald Steven
    Kurzrock, Razelle
    Amin, Hesham M.
    Fu, Siqing
    Piha-Paul, Sarina Anne
    Janku, Filip
    Zheng, Hongxia
    Sarholz, Barbara
    Johne, Andreas
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Phase II trial of the c-Met inhibitor tepotinib in advanced lung adenocarcinoma with MET exon 14 skipping mutations.
    Palk, Paul K.
    Felip, Enriqueta
    Veillon, Remi
    Scheele, Jurgen
    Bruns, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy Subjects
    Cheng, Yiming
    Wang, Xiaomin
    Liu, Liangang
    Silva, Jose
    Thomas, Michael
    Li, Yan
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2024, 49 (03) : 355 - 365
  • [6] A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy Subjects
    Yiming Cheng
    Xiaomin Wang
    Liangang Liu
    Jose Silva
    Michael Thomas
    Yan Li
    European Journal of Drug Metabolism and Pharmacokinetics, 2024, 49 : 355 - 365
  • [7] Final phase Ib data for the oral c-Met inhibitor tepotinib in patients with previously treated advanced hepatocellular carcinoma.
    Faivre, Sandrine J.
    Blanc, Jean-Frederic
    Merle, Philippe
    Fasolo, Angelica
    Iacobellis, Angelo
    Decaens, Thomas
    Villa, Erica
    Trojan, Jorg
    Grand, Veronique
    Ellers-Lenz, Barbara
    Zhao, Charles
    Raymond, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study
    Schueller, Olivier
    Skucas, Ed
    Regev, Galit
    Shaw, Iain
    Singh, Nand
    Sanghvi, Mitesh
    Croft, Marie
    Lohmer, Lauren
    Alabanza, Anginelle
    Patel, Jeegar
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (07): : 786 - 794
  • [9] Phase II Trial of the C-Met Inhibitor Tepotinib in Advanced Lung Adenocarcinoma with MET Exon 14 Skipping Mutations after Failure of Prior Therapy
    Paik, Paul
    Stammberger, Uz
    Bruns, Rolf
    Overton, Lindsay
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1230 - S1230
  • [10] A RANDOMIZED, OPEN-LABEL, CROSSOVER CLINICAL TRIAL TO EVALUATE THE ABSOLUTE ORAL BIOAVAILABILITY OF SILIBILIN (SIL-FARMA-01)
    Galvez Mugica, M. A.
    Jimenez, M. A.
    De Pablo Lopez de Abechuco, I
    Monaj, A. R.
    Serrano Olmeda, M. L.
    del Alamao Camunas, M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 12 - 12
12345